CCT6A通过STAT1/HK2轴促进肺腺癌的进展和糖解
Shao-Kun Yu1, Tao Yu1, Yu-Ming Wang2
1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Journal of translational medicine
|May 15, 2024
概括
含TCP1亚单元6A的Chaperonin (CCT6A) 通过增强STAT1稳定性和HK2转录来促进肺腺癌 (LUAD) 的进展,为这种侵袭性癌症提供了潜在的治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 含TCP1子单元6A的Chaperonin (CCT6A) 对于蛋白质折叠至关重要,但其在肺腺癌 (LUAD) 中的作用尚不清楚.
- LUAD是一种具有有限治疗选择的侵袭性癌症.
研究的目的:
- 研究CCT6A在LUAD进展中的作用和机制.
- 确定CCT6A作为LUAD的潜在治疗点.
主要方法:
- 在体外细胞表型实验 (扩散,入侵).
- 转录基因测序和LC-MS分析.
- 同免疫沉 (Co-IP) 和染色体免疫沉 (CHIP) 的测试.
主要成果:
- 在LUAD中,CCT6A过度表达,与预后不佳有关.
- 沉默CCT6A减少了LUAD细胞的增殖和迁移,增加了细胞亡.
- CCT6A通过保护STAT1免受降解而稳定STAT1,促进HK2转录和有氧糖解.
结论:
- CCT6A/STAT1/HK2轴通过代谢重编程驱动LUAD的进展.
- CCT6A代表了LUAD治疗的有前途的治疗标.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
cAMP-dependent Protein Kinase Pathways
6.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.3K
MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K


